I agree that in theory it is quite outside the FDA's ambit to make a decision based on pricing.
But it is within the FDA's discretion just how many resources to devote to a review. And they prioritize based on their judgment of "need" and these days I think it would be naive to assume pricing might not play a part here. After all, pretty much the entire rationale for generic drugs is pricing considerations.
So no, they wouldn't accept or reject Teva's application based on NVS/MNTA's pricing. But I could see them applying more or less effort to the review based partly on pricing.
Market Data 
Markets 
AI
